Eli Lilly Selects ICON To Manage Its Clinical Trial Site Set Up And Monitoring In Europe

Published: 09-Jun-2009

Eli Lilly and Company (Eli Lilly) has selected ICON plc (ICON) to manage clinical trial site set up and monitoring in Europe for Eli Lilly managed studies. The agreement, which is subject to the relevant employee consultation processes, is a continuation of Eli Lilly’s ongoing transformation of its research and development organization and follows Eli Lilly’s selection of ICON to manage its clinical data management business outside of the US.

“Today’s announcement marks another milestone in the successful partnership between ICON and Lilly,” commented Peter Gray, CEO at ICON. “We have worked together to create a truly flexible model that better meets Lilly’s patient and portfolio needs and will also drive productivity within Lilly’s clinical operations in Europe. We look forward to continuing to assist Lilly with its transformation initiatives and to delivering the quality services that will expedite their drug development pipelines.”

We are constantly evaluating how we can do things better to increase our flexibility and focus our internal efforts on our core capabilities, commented Jeff Kasher, Lilly Vice President and Chief Operating Officer of Global Clinical Development.” This strategic agreement enables us to leverage ICON's significant expertise in clinical trial monitoring and site management in Europe and will increase our ability to speed innovative medicines to patients.

ICON plc is a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.

Tell your friend about this article